Guidelines Development Group for the British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma

Affiliations

¹ Hepatology and Gastroenterology Section, Department of Medicine, Imperial College London, London, UK shahid.khan@imperial.ac.uk.
² Department of Hepatology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, UK.
³ University of Edinburgh MRC Centre for Inflammation Research, Edinburgh, UK.
⁴ Division of Pathology, University of Edinburgh, Edinburgh, UK.
⁵ King's College London, London, UK.
⁶ Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁷ Christie Hospital, Manchester, UK.
⁸ University College London, London, UK.
⁹ Digestive Diseases Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.
¹⁰ Surgery, Royal Free Campus, UCL Medical School, London, UK.
¹¹ Surgery, University Hospital Aintree, Liverpool, UK.
¹² Newcastle University, Newcastle upon Tyne, UK.
¹³ Department of Hepatobiliary and Pancreatic Surgery, King's College London, London, UK.
¹⁴ John Goligher Colorectal Unit, St. James University Hospital, Leeds, UK.
¹⁵ Medical Oncology, The Christie NHS Foundation Trust/University of Manchester, Manchester, UK.
¹⁶ St James's University Hospital, Leeds, UK.
¹⁷ Department of Medical Physics and Biomedical Engineering, University College London, London, UK.
¹⁸ King's College Hospital, London, UK.
¹⁹ AMMF, Essex, UK.
²⁰ Chair of Trustees PSC Support, Didcot, UK.
²¹ Department of Oncology, UCL Cancer Institute, University College London, London, UK.

Shahid A Khan et al. Gut. 2025.

. 2025 Feb 6;74(3):504-505.

doi: 10.1136/gutjnl-2024-333359.

¹ Hepatology and Gastroenterology Section, Department of Medicine, Imperial College London, London, UK shahid.khan@imperial.ac.uk.
² Department of Hepatology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, UK.
³ University of Edinburgh MRC Centre for Inflammation Research, Edinburgh, UK.
⁴ Division of Pathology, University of Edinburgh, Edinburgh, UK.
⁵ King's College London, London, UK.
⁶ Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁷ Christie Hospital, Manchester, UK.
⁸ University College London, London, UK.
⁹ Digestive Diseases Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.
¹⁰ Surgery, Royal Free Campus, UCL Medical School, London, UK.
¹¹ Surgery, University Hospital Aintree, Liverpool, UK.
¹² Newcastle University, Newcastle upon Tyne, UK.
¹³ Department of Hepatobiliary and Pancreatic Surgery, King's College London, London, UK.
¹⁴ John Goligher Colorectal Unit, St. James University Hospital, Leeds, UK.
¹⁵ Medical Oncology, The Christie NHS Foundation Trust/University of Manchester, Manchester, UK.
¹⁶ St James's University Hospital, Leeds, UK.
¹⁷ Department of Medical Physics and Biomedical Engineering, University College London, London, UK.
¹⁸ King's College Hospital, London, UK.
¹⁹ AMMF, Essex, UK.
²⁰ Chair of Trustees PSC Support, Didcot, UK.
²¹ Department of Oncology, UCL Cancer Institute, University College London, London, UK.

No abstract available

Keywords: CHOLANGIOCARCINOMA.

Conflict of interest statement

Competing interests: None declared.

1. Rushbrook SM, Kendall TJ, Zen Y, et al. British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut. 2023;73:16–46. doi: 10.1136/gutjnl-2023-330029. - DOI - PMC - PubMed
1. NICE Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944) 2024. https://www.nice.org.uk/guidance/ta944/resources/durvalumab-with-gemcita... Available.
1. Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:127–40. doi: 10.1016/j.annonc.2022.10.506. - DOI - PubMed